Paratek Pharmaceuticals Company Profile (NASDAQ:PRTK)

About Paratek Pharmaceuticals

Paratek Pharmaceuticals logoParatek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek's antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). The Company's sarecycline is a Phase III antibacterial product candidate and was previously known as WC3035. Sarecycline is designed for use in the treatment of acne and rosacea. The Company's other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: PRTK
  • CUSIP: 89354M10
Key Metrics:
  • Previous Close: $13.25
  • 50 Day Moving Average: $13.07
  • 200 Day Moving Average: $14.35
  • 52-Week Range: $12.05 - $28.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.37
  • P/E Growth: -0.01
  • Market Cap: $300.49M
  • Outstanding Shares: 22,627,000
  • Beta: 0.17
Additional Links:
Companies Related to Paratek Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Paratek Pharmaceuticals (NASDAQ:PRTK) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $38.43 (187.64% upside)

Analysts' Ratings History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Show:
DateFirmActionRatingPrice TargetDetails
8/16/2016GuggenheimReiterated RatingBuyView Rating Details
8/16/2016HC WainwrightReiterated RatingBuyView Rating Details
6/29/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details
6/17/2016BTIG ResearchReiterated RatingBuy$45.00View Rating Details
6/17/2016Robert W. BairdReiterated RatingOutperform$30.00 -> $40.00View Rating Details
6/17/2016Ladenburg ThalmannBoost Price TargetBuy$46.00 -> $52.00View Rating Details
5/15/2016Leerink SwannReiterated RatingBuy$35.00View Rating Details
7/22/2015GabelliInitiated CoverageBuy$34.00View Rating Details
(Data available from 8/30/2014 forward)

Earnings

Earnings History for Paratek Pharmaceuticals (NASDAQ:PRTK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016        
8/4/2016Q2($1.66)($1.69)ViewN/AView Earnings Details
5/2/2016($1.25)($1.77)ViewN/AView Earnings Details
2/23/2016Q4($1.18)($1.20)ViewListenView Earnings Details
11/12/2015Q315($0.91)($1.33)ViewListenView Earnings Details
8/5/2015Q215($0.75)($0.94)$3.62 billionViewN/AView Earnings Details
5/18/2015Q1($2.16)($0.74)ViewN/AView Earnings Details
5/5/2014($0.18)($0.15)ViewN/AView Earnings Details
3/13/2014Q413($0.21)($0.29)$0.50 million$0.32 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.42)($0.56)ViewN/AView Earnings Details
11/12/2012Q312$0.06$0.25$8.37 million$10.44 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)
Next Year EPS Consensus Estimate: $-3.96 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($1.29)($1.29)($1.29)
Q2 20162($1.64)($1.32)($1.48)
Q3 20162($1.38)($1.36)($1.37)
Q4 20162($1.39)($1.28)($1.34)
(Data provided by Zacks Investment Research)

Dividends


Dividend History for Paratek Pharmaceuticals (NASDAQ:PRTK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/14/2014special$1.336/4/20145/26/20146/3/2014
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/27/2016Fund Iv L.P. OmegaMajor ShareholderBuy461,538$13.00$5,999,994.00View SEC Filing  
6/23/2016Michael BighamCEOBuy20,000$13.45$269,000.00View SEC Filing  
12/11/2015Evan LohCMOBuy2,300$16.87$38,801.00View SEC Filing  
5/29/2015Hbm Healthcare Investments (CaMajor ShareholderSell20,580$30.75$632,835.00View SEC Filing  
12/13/2013Roumell Asset Management, Llcmajor shareholderSell1,470$3.54$5,203.80View SEC Filing  
12/11/2013Roumell Asset Management, Llcmajor shareholderSell10,490$3.55$37,239.50View SEC Filing  
12/6/2013Roumell Asset Management, Llcmajor shareholderSell8,710$3.54$30,833.40View SEC Filing  
12/4/2013Roumell Asset Management, Llcmajor shareholderSell7,120$3.50$24,920.00View SEC Filing  
11/20/2013Roumell Asset Management, Llcmajor shareholderSell10,040$3.57$35,842.80View SEC Filing  
11/12/2013Roumell Asset Management, Llcmajor shareholderSell7,190$3.53$25,380.70View SEC Filing  
11/7/2013Roumell Asset Management, Llcmajor shareholderSell4,960$3.61$17,905.60View SEC Filing  
10/30/2013Roumell Asset Management, LlcMajor ShareholderSell7,020$3.69$25,903.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Paratek Pharmaceuticals (NASDAQ:PRTK)
DateHeadline
News IconShares Down for the Quarter: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Post News (NASDAQ:PRTK)
www.kentuckypostnews.com - August 28 at 6:05 PM
News IconIs Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) a Buy According to the Crowd? - Post News (NASDAQ:PRTK)
www.kentuckypostnews.com - August 20 at 10:56 AM
streetinsider.com logoParatek Pharmaceuticals (PRTK) Doses First Patient in Phase 3 Study of Oral-only Omadacycline in ABSSSI - StreetInsider.com (NASDAQ:PRTK)
www.streetinsider.com - August 16 at 10:10 AM
4-traders.com logoParatek Initiates Phase 3 Study of Oral-only Omadacycline in ABSSSI (NASDAQ:PRTK)
www.4-traders.com - August 15 at 9:06 AM
finance.yahoo.com logoPARATEK PHARMACEUTICALS, INC. Financials (NASDAQ:PRTK)
finance.yahoo.com - August 11 at 7:26 PM
ftsenews.co.uk logoParatek Pharmaceuticals, Inc. (PRTK) Updated Price Targets - FTSE News (NASDAQ:PRTK)
www.ftsenews.co.uk - August 10 at 10:02 AM
globenewswire.com logoParatek Pharmaceuticals, Inc. Reports Second Quarter 2016 Financial and Operating Results (NASDAQ:PRTK)
globenewswire.com - August 4 at 10:06 AM
sg.finance.yahoo.com logoParatek reports 2Q loss (NASDAQ:PRTK)
sg.finance.yahoo.com - August 4 at 10:06 AM
4-traders.com logoParatek Pharmaceuticals : Announces Closing of Common Stock Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares (NASDAQ:PRTK)
www.4-traders.com - July 22 at 6:47 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - TGP (NASDAQ:PRTK)
telanaganapress.com - July 22 at 9:54 AM
fiscalstandard.com logoParatek Pharmaceuticals, Inc. (PRTK) Current Analyst Ratings ... - Fiscal Standard (NASDAQ:PRTK)
www.fiscalstandard.com - July 22 at 9:54 AM
News IconParatek Pharmaceuticals, Inc. (NASDAQ:PRTK): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:PRTK)
www.engelwooddaily.com - July 20 at 9:48 AM
ftsenews.co.uk logoNew Broker Ratings For Paratek Pharmaceuticals, Inc. (PRTK) - FTSE News (NASDAQ:PRTK)
www.ftsenews.co.uk - July 20 at 9:48 AM
News IconTrading Performance and Target Watch for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Press Telegraph (NASDAQ:PRTK)
presstelegraph.com - July 18 at 7:02 PM
News IconParatek Pharmaceuticals Inc's Trend Down, Especially After Forming a Multiple Bottom - Press Telegraph (NASDAQ:PRTK)
presstelegraph.com - July 18 at 7:02 PM
kcregister.com logoFlagstar Bancorp Inc. (NYSE:FBC) Rose 0.04%: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), NuVasive, Inc ... - KC Register (NASDAQ:PRTK)
www.kcregister.com - July 16 at 10:13 AM
fiscalstandard.com logoBroker Outlook For Paratek Pharmaceuticals, Inc. (PRTK) - Fiscal Standard (NASDAQ:PRTK)
www.fiscalstandard.com - July 16 at 10:13 AM
News IconCrowd Rating and Earnings Recap for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Telanagana Press (NASDAQ:PRTK)
telanaganapress.com - July 14 at 10:34 AM
News IconAnalyst Target and Average Rating Watch: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Press Telegraph (NASDAQ:PRTK)
presstelegraph.com - July 13 at 7:21 PM
News IconParatek Pharmaceuticals Incorporated (NASDAQ:PRTK) Shorted Shares Decreased By 6.44% - Press Telegraph (NASDAQ:PRTK)
presstelegraph.com - July 12 at 11:20 AM
News IconHow Many Paratek Pharmaceuticals Inc (NASDAQ:PRTK)'s Analysts Are Bearish? - Press Telegraph (NASDAQ:PRTK)
presstelegraph.com - July 9 at 10:04 AM
streetupdates.com logoMost recent Analysts Rating report: Seattle Genetics, Inc. (NASDAQ:SGEN) , Paratek Pharmaceuticals, Inc. (NASDAQ ... - Street Updates (NASDAQ:PRTK)
www.streetupdates.com - July 5 at 11:25 AM
fiscalstandard.com logoParatek Pharmaceuticals, Inc. (PRTK) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:PRTK)
www.fiscalstandard.com - July 4 at 6:08 PM
News IconSell-Side Recommendation & Price Target Projections on Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Telanagana Press (NASDAQ:PRTK)
telanaganapress.com - June 30 at 7:11 PM
4-traders.com logoParatek Pharmaceuticals : Announces Closing of Common Stock Offering and Exercise in Full of Underwriters Option to Purchase Additional Shares (NASDAQ:PRTK)
www.4-traders.com - June 29 at 9:43 AM
News IconEquity Research and Technical Review on Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Press Telegraph (NASDAQ:PRTK)
presstelegraph.com - June 28 at 6:51 PM
News IconShare Update and Earnings Review for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Press Telegraph (NASDAQ:PRTK)
presstelegraph.com - June 28 at 6:51 PM
nasdaq.com logoTuesday 6/28 Insider Buying Report: LNG, PRTK (NASDAQ:PRTK)
www.nasdaq.com - June 28 at 11:47 AM
4-traders.com logoParatek Pharmaceuticals : Announces Pricing of Public Offering of 4,250,000 Shares of Common Stock (NASDAQ:PRTK)
www.4-traders.com - June 27 at 6:55 PM
finance.yahoo.com logoParatek Announces Closing of Common Stock Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares (NASDAQ:PRTK)
finance.yahoo.com - June 27 at 6:55 PM
tradecalls.org logoLadenburg Thalmann Maintains Paratek Pharmaceuticals Inc to Buy with Price Target $52.00 - Trade Calls (NASDAQ:PRTK)
www.tradecalls.org - June 26 at 6:01 PM
streetupdates.com logoTwo Movers inside Analysts Radar: Bristol-Myers Squibb Company (NYSE:BMY) , Paratek Pharmaceuticals, Inc ... - Street Updates (NASDAQ:PRTK)
www.streetupdates.com - June 23 at 9:35 AM
news.cmlviz.com logoParatek Pharmaceuticals, Inc. (NasdaqGM:PRTK) Stock Momentum Hits Weakness - CML News (NASDAQ:PRTK)
news.cmlviz.com - June 23 at 9:35 AM
finance.yahoo.com logoParatek Announces Pricing of Public Offering of 4,250,000 Shares of Common Stock (NASDAQ:PRTK)
finance.yahoo.com - June 22 at 6:53 PM
biz.yahoo.com logoPARATEK PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events (NASDAQ:PRTK)
biz.yahoo.com - June 22 at 5:07 PM
News IconSizzling Stocks Alert - Whiting Petroleum, (NYSE:WLL), Paratek Pharmaceuticals, (NASDAQ:PRTK) - Hot Stocks Point (NASDAQ:PRTK)
www.hotstockspoint.com - June 22 at 11:40 AM
streetinsider.com logoParatek Pharmaceuticals (PRTK) Prices 4.25M Common Stock Offering at $13/Share - StreetInsider.com (NASDAQ:PRTK)
www.streetinsider.com - June 22 at 11:40 AM
tradecalls.org logoParatek Pharmaceuticals (NASDAQ:PRTK) Analyst Rating Consensus - Trade Calls (NASDAQ:PRTK)
www.tradecalls.org - June 22 at 11:40 AM
4-traders.com logoParatek Pharmaceuticals : Announces Proposed Public Offering of Common Stock (NASDAQ:PRTK)
www.4-traders.com - June 21 at 6:30 PM
finance.yahoo.com logoParatek Announces Proposed Public Offering of Common Stock (NASDAQ:PRTK)
finance.yahoo.com - June 21 at 11:17 AM
streetinsider.com logoParatek Pharmaceuticals (PRTK) Expects to Present Omadacycline Phase 1b Data in Q416 - StreetInsider.com (NASDAQ:PRTK)
www.streetinsider.com - June 20 at 6:42 PM
publicnow.com logoParatek Announces that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections; Omadacycline was Generally Safe and Well-Tolerated (NASDAQ:PRTK)
www.publicnow.com - June 20 at 8:19 AM
finance.yahoo.com logoParatek Accelerates Timing for Projected Reporting of Top-Line Data for Omadacycline Phase 1b Urinary Tract Infection Study (NASDAQ:PRTK)
finance.yahoo.com - June 20 at 8:00 AM
investing.com logoParatek Spikes On Study Results (NASDAQ:PRTK)
www.investing.com - June 19 at 10:46 AM
rttnews.com logoParatek Pharmaceuticals Inc. (PRTK) Is Rising On Phase 3 Study News (NASDAQ:PRTK)
www.rttnews.com - June 19 at 10:46 AM
News IconHome Biotech Stocks Paratek Pharmaceuticals, Inc. | $PRTK Stock | Shares Spike Up On Positive... - TickerTV News (press release) (NASDAQ:PRTK)
ticker.tv - June 18 at 11:05 AM
schaeffersresearch.com logoBuzz Stocks: Smith & Wesson Holding Corp, Paratek Pharmaceuticals Inc, and Lumber Liquidators Holdings Inc - Schaeffers Research (blog) (NASDAQ:PRTK)
www.schaeffersresearch.com - June 17 at 6:44 PM
publicnow.com logoParatek Pharmaceuticals Announces Positive Phase 3 Results for its Antibiotic Omadacyline (NASDAQ:PRTK)
www.publicnow.com - June 17 at 12:19 PM
schaeffersresearch.com logoBuzz Stocks: Smith & Wesson Holding Corp, Paratek Pharmaceuticals Inc, and Lumber Liquidators Holdings Inc (NASDAQ:PRTK)
www.schaeffersresearch.com - June 17 at 9:42 AM
rttnews.com logoParatek Pharmaceuticals Inc. (PRTK) Is Climbing On Phase 3 Results (NASDAQ:PRTK)
www.rttnews.com - June 17 at 9:42 AM

Social

Paratek Pharmaceuticals (NASDAQ:PRTK) Chart for Tuesday, August, 30, 2016


Last Updated on 8/30/2016 by MarketBeat.com Staff